GeneralConnection.com ➔ Dictionary
Dictionary Search

myelofibrosis

Synonyms

Noun

1. fibrosis

Usage
A Transformative Study for an Unmet Clinical Need: Myelofibrosis - Fox Chase Cancer Center
INCA033989 May Address Unmet Need in Mutant Calreticulin Myelofibrosis: Claire Harrison, MD - The American Journal of Managed Care® (AJMC®)
CAR T Cell Therapy Shows Promise for Myelofibrosis - EMJ
Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Met First Co-Primary Endpoint, Demonstrating Statistically Significant Improvement in Spleen Volume Reduction - Karyopharm
Management of splenomegaly in patients with myelofibrosis in the era of JAK inhibitors: a comprehensive review - Frontiers
When Should You Employ Transplantation in Myelofibrosis Therapy? - CancerNetwork
Interferon Therapy Improves Survival in Early Myelofibrosis - Hematology Advisor
Rovadicitinib, a first-in-class JAK/ROCK inhibitor, in patients with myelofibrosis: a preclinical and phase I study - Nature
Imetelstat Demonstrates Survival Benefit in R/R Myelofibrosis Vs Real-World Data - Oncology Nursing News
Phase 3 SENTRY Trial Shows Progress in Myelofibrosis Care - Cure Today
Evolving Strategies for Myelofibrosis-Associated Anemia Highlight Persistent Gaps in Biomarker Guidance - OncLive
JAK inhibitor selection in challenging scenarios of myelofibrosis: a review - Haematologica
Syndax Pharmaceuticals Maps Growth Beyond Revuforj With Lung Cancer, Myelofibrosis Push - MarketBeat
INCA033989 Shows Potential as a Targeted Approach for Myelofibrosis With Mutant Calreticulin: Claire Harrison, MD - The American Journal of Managed Care® (AJMC®)
Triple-negative primary myelofibrosis: a comparative analysis of phenotype, genotype, and outcome - Nature
Latest Advancements in Myelofibrosis Treatment: Key Updates from EHA and ASH 2025 - EMJ
Luspatercept Misses Primary RBC-TI End Point But Shows Clinically Meaningful Improvement for Anemia in Myelofibrosis - OncLive
Pacritinib in transplant-eligible myelofibrosis: final analysis of the phase II HOVON-134 trial - Nature
Dr Hunter on Luspatercept and Other Treatment Options for Anemia in Myelofibrosis - OncLive
Artificial intelligence differentiates prefibrotic primary myelofibrosis with thrombocytosis from essential thrombocythemia using digitized bone marrow biopsy images | Leukemia - Nature
Early Results Demonstrate Safety and Efficacy of Mutant Calreticulin–Specific Monoclonal Antibody in Myelofibrosis - The ASCO Post
Selinexor Combo Improves Spleen Volume Reduction in Myelofibrosis - CancerNetwork
Ipsen pens $1.7B deal to acquire Kartos for potential Jakafi add-on therapy for myelofibrosis - Fierce Biotech
An Educational Overview of Newly Diagnosed Stage 1 Myelofibrosis - Cure Today
Momelotinib Combo is Safe and Helps Ease Symptoms in Myelofibrosis - Cure Today
Echocardiographic High-Output Heart Failure Predicts Worse Survival in Myelofibrosis - Hematology Advisor
Jakafi XR Approved for Myelofibrosis, Polycythemia Vera, and GVHD - Hematology Advisor
Imetelstat Sustains Significant Survival Benefit in R/R Myelofibrosis - Targeted Oncology
Retrospective Data Highlight Challenges, Potential Therapeutic Strategies With Allo-HSCT in Myelofibrosis and BP-MPNs - OncLive
FDA Clears Protocol Update for Tasquinimod in Myelofibrosis Trial - Cure Today
Karyopharm's Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis Selected for Late-Breaking Oral Presentation at EHA 2026 - PR Newswire
DISC-0974 Produces Meaningful Hematologic Responses in Myelofibrosis-Associated Anemia - Targeted Oncology
Precision medicine in myelofibrosis: from molecular profiling to personalized therapy - Frontiers
FDA Approves Once-Daily Jakafi XR for Myelofibrosis and Other Conditions - Cure Today
In Intermediate-Risk Myelofibrosis, Experts Focus on Symptom Relief - Targeted Oncology
Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress - PR Newswire
Karyopharm myeloma drug yields mixed data in myelofibrosis trial - BioPharma Dive
SENTRY Trial Shows Survival, Spleen Benefits in Myelofibrosis: Claire Harrison, MD - The American Journal of Managed Care® (AJMC®)
Dr Kuykendall on Evolving JAK Inhibitor and Transplant Considerations in Myelofibrosis - OncLive
How Selinexor Plus Ruxolitinib Could Affect Frontline Myelofibrosis Management - OncLive
Karyopharm Announces Preliminary Unaudited 2025 Revenue and Reiterates Expectation of Delivering Potentially Transformative Phase 3 Data in 2026 - Karyopharm
Inflammatory mediators differentially regulate megakaryopoiesis and thrombopoiesis in myelofibrosis and essential thrombocythemia - Nature
FDA Approves Ruxolitinib Extended-Release Tablets for Myelofibrosis, Polycythemia Vera, and GVHD - Docwire News
Karyopharm to Host Investor Conference Call Featuring Expert Perspectives on the Phase 3 SENTRY Trial in Myelofibrosis Following 2026 ASCO Presentation - PR Newswire
FDA Orphan Drug Designation Granted to Zavabresib for Myelofibrosis - Cure Today
'Provocative' Survival Result in Myelofibrosis Trial - MedPage Today
PIM-1 Inhibition Offers a Novel Approach in Myelofibrosis - Targeted Oncology
New Treg Therapy Earns FDA Orphan Drug Designation in Myelofibrosis - CancerNetwork
Dual Antibodies Beat Single for Type 1 CALR-Mutant Myelofibrosis - Targeted Oncology
Scientists Uncover New Treatment for Bone Marrow Cancer - MetroHealth
Myelofibrosis (MF) in 2026: Matching Therapy to the Dominant Clinical Problem - Oncodaily
Emerging Therapeutic Strategies Transforming Myelofibrosis Care in 2026 - Pharmacy Times
Selinexor and Ruxolitinib Combo Shows Promise for Myelofibrosis - Oncology News Central
Selinexor Plus Ruxolitinib Hits SVR Primary End Point in Myelofibrosis - OncLive
NFκB/IL-6/JAK2/STAT axis in myelofibrosis is a key vulnerability that is targetable and relevant to JAK2 inhibitor treatment resistance | Blood Cancer Journal - Nature
Reassessing the Prognostic Weight of Anemia Plus Thrombocytopenia in Primary Myelofibrosis - Pharmacy Times
Sequential treatment with ruxolitinib and imetelstat effectively depletes myelofibrosis hematopoietic stem and progenitor cells | Leukemia - Nature
Early Results Demonstrate Safety and Efficacy of Mutant Calreticulin–Specific Monoclonal Antibody in Myelofibrosis - The ASCO Post
Metformin Reduces BM Fibrosis and JAK-STAT Signaling in PMF - Hematology Advisor
Treatment-relevant misdiagnosis of autoimmune myelofibrosis - Haematologica
A European survey on allogeneic haematopoietic cell transplantation for myelofibrosis on behalf of the Chronic Malignancies Working Party of the EBMT: focus on ‘real world’ experience of JAK inhibitors, splenomegaly management and novel agents in the tra - Nature
Novel strategies targeting mutant calreticulin in essential thrombocythemia and myelofibrosis - ScienceDirect.com
Karyopharm’s Phase III myelofibrosis trial delivers mixed results - Clinical Trials Arena
Early-Stage PIM-1 Kinase Inhibitors Explored in Myelofibrosis - Targeted Oncology
New Data Support Pelabresib Combination in Untreated Myelofibrosis - Cure Today
Peri-Transplant Ruxolitinib Leads to Low GVHD Incidence in Myelofibrosis - OncLive
Ipsen buys Kartos in $1.75bn myelofibrosis push - European Biotechnology Magazine
Nutritional Status Shown to Strongly Predict Survival in Patients With MF - Hematology Advisor
FDA Grants Orphan Drug Designation to CK0804 for Myelofibrosis - Cure Today
AJ1-11095 Receives Orphan Drug Designation From the FDA in Myelofibrosis - OncLive
Earlier Momelotinib Treatment Is Associated With Improved Outcomes in Patients WIth Myelofibrosis - HMP Global Learning Network
Momelotinib May Not Be Cost-Effective Intervention for Myelofibrosis or Anemia - Hematology Advisor
Long-Term Consequences of Myelofibrosis and the Impact of Early Intervention - Pharmacy Times
Navigating the Expanding Landscape of Myelofibrosis Treatment - Pharmacy Times
Cutaneous Extramedullary Hematopoiesis in Primary Myelofibrosis: A Case Report With Rapidly Fatal Outcome - Cureus
FDA Grants Orphan Drug Status to Zavabresib for Myelofibrosis Therapy - Hematology Advisor
Machine learning identifies inflammation-related diagnostic biomarkers for primary myelofibrosis with clinical validation - Nature
Zavabresib Granted Orphan Drug Designation for Myelofibrosis - Targeted Oncology
Selinexor Plus Ruxolitinib Meets Primary Endpoint in Myelofibrosis Trial - The Clinical Trial Vanguard
GSK secures Omjjara reimbursement in Korea, expanding access for myelofibrosis patients - koreabiomed.com
The SENTRY Trial: Selinexor Plus Ruxolitinib in JAK Inhibitor–Naive Myelofibrosis - OncLive
FDA Grants Orphan Drug Designation to Cellenkos' CK0804 Treg Therapy for Treatment of Myelofibrosis - PR Newswire
Optimizing Future Combination Approaches in Myelofibrosis - OncLive
Karyopharm to Present Results from Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis in Late-Breaking Oral Presentation at ASCO 2026 with Simultaneous Publication in the Journal of Clinical Oncology - PR Newswire
Nuvisertib Yields Strong Safety, Promising Efficacy in R/R Myelofibrosis - OncLive
Selinexor Plus Ruxolitinib Improves Spleen Responses, Shows OS Signal in Frontline Myelofibrosis - Targeted Oncology
Ultraprecision Targeting of CALR Mutations Signals a New Era in Myelofibrosis Treatment - Pharmacy Times
Myelofibrosis Survivor Reflects on the Impact of Her Physician - Cure Today
FDA-Approved JAK Inhibitors in Myelofibrosis: Mechanisms, Indications, and Clinical Impact - Pharmacy Times
Selective BET Inhibition With ABBV-744 Shows Early Clinical Activity in Myelofibrosis - Pharmacy Times
Vonjo Improves Blood Counts in Patients With Myelofibrosis and Anemia - Cure Today
Pelabresib Plus Ruxolitinib Benefits Spleen, Symptoms in Myelofibrosis - Targeted Oncology
JAK Inhibitors Expand Treatment Options in Polycythemia Vera and Myelofibrosis - OncLive
Zavabresib Earns FDA Orphan Drug Designation in Myelofibrosis - CancerNetwork
Early Data for Tagraxofusp Support Further Evaluation in Combination Therapies in Myelofibrosis - OncLive
Opna Bio’s OPN-2853 secures FDA’s orphan drug status for myelofibrosis - Pharmaceutical Technology
Cellenkos gains FDA orphan drug status for CK0804 to treat myelofibrosis - Pharmaceutical Technology
JAK Inhibitors Persist, While Novel Agents Aim for Disease Modification in Myelofibrosis - OncLive
Anemia Management in Myelofibrosis: Survival and Quality of Life - Cure Today
POIESIS Trial Evaluates Navtemadlin/Ruxolitinib Combo in Myelofibrosis - Oncology Nursing News
Foreign Language Equivalents
Foreign Language Equivalents of 'myelofibrosis'
Language Equivalent   Language Equivalent
French    Spanish
Misspellings - Typos
mylofibrosis,   yelofibrosis,   myelofibross,   meylofibrosis,   myelofibeosis,   myekofibrosis,   myelfoibrosis,   myelofibbrosis,   myelofibosis,   myelpfibrosis,   mye;ofibrosis,   myelofirbosis,   myyelofibrosis,   myelofibrosid,   myelofibrosus,   myelofiibrosis,   ymelofibrosis,   myelofbrosis,   myelofibrosia,   myelofibrosiss,   melofibrosis,   myleofibrosis,   myelfibrosis,   myelofibrrosis,   myelofibroosis,   myelofibrossi,   myeloibrosis,   myeofibrosis,   myelofibrois,   myelofivrosis,   myelofbirosis,   myeloofibrosis,   muelofibrosis,   myelofibrsis,   myelifibrosis,   myelofibrosi,   myelofibrpsis,   myelodibrosis,   myelofibroiss,   myelofibrosiis,   myelofibrosos,   myelofinrosis,   myelofibrisis,   myelofibrossis,   myelofibrodis,   myellofibrosis,   myelogibrosis,   myelofubrosis,   mywlofibrosis,   myeloifbrosis,   myeelofibrosis,   myeolfibrosis,   myelofibroais,   myelofobrosis,   myelofiborsis,   nyelofibrosis,   mmyelofibrosis,   myelofibrsois,   myrlofibrosis,   ,yelofibrosis,   myeloffibrosis,   mtelofibrosis,   myelofirosis,   myelofibtosis
Words Starting with Letter - 'A'
a a battery a billion
a bit a bit much a capella singing
a cappella singing a couple of a few
a fortiori a good deal a great deal
a horizon a hundred a hundred and one
a hundred thousand a hundred times a kempis
a la carte a la mode a level
a little a lot a million
Go to Page 1              Go to Page 2 »   
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z